Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gibb

Showing results (311-320 of 368) with videos related to

Pageof 37
Sort By:
Lancet (London, England)|November 12, 2013
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trialMark F Cotton, Avy Violari, Kennedy Otwombe, et al.
Emerging Infectious Diseases|January 20, 2018
Development of a Pediatric Ebola Predictive Score, Sierra Leone<sup>1</sup>Felicity Fitzgerald, Kevin Wing, Asad Naveed, et al.
BMC Health Services Research|November 18, 2016
Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline studyMisheck J Nkhata, Margaret Muzambi, Deborah Ford, et al.
The New England Journal of Medicine|December 18, 2024
Levofloxacin Preventive Treatment in Children Exposed to MDR TuberculosisAnneke C Hesseling, Susan E Purchase, Neil A Martinson, et al.
BMC Health Services Research|August 21, 2014
The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and ZimbabweAdrienne K Chan, Deborah Ford, Harriet Namata, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
Expert Opinion on Pharmacotherapy|August 19, 2007
Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendationsElke H J Krekels, John N van den Anker, Paola Baiardi, et al.
JAMA|November 2, 2021
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical TrialJulia A Bielicki, Wolfgang Stöhr, Sam Barratt, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2024
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIVLufina Tsirizani, Shaghayegh Mohsenian Naghani, Hylke Waalewijn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
Pageof 37

Showing results (311-320 of 368) with videos related to

Sort By:
Pageof 37
Lancet (London, England)|November 12, 2013
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trialMark F Cotton, Avy Violari, Kennedy Otwombe, et al.
Emerging Infectious Diseases|January 20, 2018
Development of a Pediatric Ebola Predictive Score, Sierra Leone<sup>1</sup>Felicity Fitzgerald, Kevin Wing, Asad Naveed, et al.
BMC Health Services Research|November 18, 2016
Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline studyMisheck J Nkhata, Margaret Muzambi, Deborah Ford, et al.
The New England Journal of Medicine|December 18, 2024
Levofloxacin Preventive Treatment in Children Exposed to MDR TuberculosisAnneke C Hesseling, Susan E Purchase, Neil A Martinson, et al.
BMC Health Services Research|August 21, 2014
The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and ZimbabweAdrienne K Chan, Deborah Ford, Harriet Namata, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
Expert Opinion on Pharmacotherapy|August 19, 2007
Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendationsElke H J Krekels, John N van den Anker, Paola Baiardi, et al.
JAMA|November 2, 2021
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical TrialJulia A Bielicki, Wolfgang Stöhr, Sam Barratt, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2024
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIVLufina Tsirizani, Shaghayegh Mohsenian Naghani, Hylke Waalewijn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
Pageof 37